Clinical Trial

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Name: JSKN003 Combined Treatment of HER2-positive Gastric Cancer — clinical trial record (NCT06998771)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.

Trial Details

NCT Number	NCT06998771
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	HER2-positive Gastric Cancer
Enrollment	153 participants
Start Date	2025-06-15
Primary Completion	2028-06-30 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-05-31